Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease. Letter to the editor - Jessen, Frank; Arbizu, Javier; Boada, Mercé; Balasa, Mircea; Bennys, Karim; Boban, Marina; Buerger, Katharina; Chincarini, Andrea; Cagnin, Annachiara; De Deyn, Peter Paul; Düzel, Emrah; Engelborghs, Sebastiaan; et al. (The journal of prevention of Alzheimer's disease, 2025)
Online verfügbar: 9. Juli 2025, Artikelversion: 27. August 2025